Vivus
INVA$899M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBURLINGAME
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Mar 31, 2026
3dMarket Overview
Stock performance and key metrics
INVA News
Catalyst Timeline
2 upcoming, 1 past
Phase 2Next
VI-0609 Phase 2 Results Expected
Mar 31, 2026EstimatedVI-060949
Primary completion for VI-0609 trial (NCT06915246) in Lymphoma
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
VI-0521
Obesity
avanafil
Erectile Dysfunction
VI-1121
Alzheimer's Disease
Phentermine/Topiramate
Diabetes
Topical alprostadil (PGE-1)
Sexual Dysfunction, Physiological
VI-0609
Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VI-0521 | Phase 3 | Obesity | - | - |
avanafil | Phase 3 | Erectile Dysfunction | - | - |
VI-1121 | Phase 2 | Alzheimer's Disease | - | - |
Phentermine/Topiramate | Phase 2 | Diabetes | - | - |
Topical alprostadil (PGE-1) | Phase 2 | Sexual Dysfunction, Physiological | - | - |
VI-0609 | Phase 2 | Lymphoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply